logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Pfizer and BioNTech Submitted an EUA to the FDA for their COVID-19 Vaccine, BNT162b2

Pfizer, BioNTech & Moderna When asked whether we heard the news about the submission of the Emergency Use Authorization (EUA) and whether we will inform our readers about it. Our answer was that we have posted many articles about Pfizer's...

Read More

November 21, 2020

0

Regeneron Granted FDA Emergency Use Authorization for its COVID-19 Antibody Cocktail Therapy

Regeneron Pharmaceuticals Receives EUA from the FDA for REGEN-COV2 Regeneron Pharmaceuticals’ ( REGN ) antibody cocktail therapy casirivimab and imdevimab, known also REGN-COV2 or REGEN-COV2 , received Emergency Use Authorization ( EUA ) from the U.S. Food and Drug Administration...

Read More

November 22, 2020

0

The Latest from Reata Pharmaceuticals. See Also: Prohost Picks that Reached the Moon in Today's Trading

Reata Pharmaceuticals We picked Reata Pharmaceuticals ( RETA ) for investment after confirming that the products the Company has created and is currently developing have a novel mechanism of action that enables the treatment of severe diseases that have yet...

Read More

November 27, 2020

0

The FDA Approved Rhythm Pharmaceuticals Product IMCIVREE™ for Genetic Obesity due to POMC, PCSK1 or LEPR Deficiency

Rhythm Pharmaceuticals FDA Approval of IMCIVREE™ for Genetic Obesity At the end of the trading week last Friday, November 27, 2020, the United States FDA approved Rhythm Pharmaceuticals’ ( RYTM ) product IMCIVREE™ (setmelanotide). The product is designed to treat...

Read More

December 1, 2020

0

Why Intellia Therapeutics' and Moderna's Stocks Moved South Yesterday

Intellia Therapeutics Intellia Therapeutics ( NTLA ) stock price headed south probably because some robots learned that the firm commenced an underwritten public offering of $150 million of shares of its common stock. In addition to the commenced public offering Intellia announced...

Read More

December 2, 2020

0

A Biotech Firm We Love to Discover

Rubius Therapeutics Finding small development-stage biotech firms that contribute to biotechnology's limitless revolution of the biological sciences is difficult, but indispensable. Falling on firms that might have the science, the technological capability and the inspiration towards creating new diagnostics and...

Read More

March 30, 2021

0

Exelixis CABOMETYX: Now Approved in Europe for First-Line Treatment of Renal Cell Carcinoma

Exelixis Boxed in on Good News Exelixis ( EXEL ) is one of the firms boxed in by rule of thumb traders and short-sellers who put enormous pressure on biotech firms regardless of their good news. We sincerely believe that...

Read More

April 1, 2021

0

Intellia Therapeutics Announces More Good News

Intellia Therapeutics NTLA-2001 for ATTR Granted Orphan Drug Designation by the EC Intellia Therapeutics ( NTLA ) announced that the European Commission (EC) has granted its product NTLA-2001 orphan drug designation. The investigational product is being developed as a treatment for transthyretin...

Read More

April 5, 2021

0

Our Third Gene-Editing Pick is Joining its Two Sisters on the Road to Great Performances

CRISPR, Intellia and Editas, Our Gene-Editing Sisters, are Rallying The three CRISPR gene-editing firms that we have chosen are enjoying rallies.  CRISPR Therapeutics ( CRSP ) and Intellia Therapeutics ( NTLA ) stocks’ rallying were the first to move products...

Read More

December 10, 2020

0

Acquisitions that Make Sense

Acquisitions  AstraZeneca Acquires Alexion Pharmaceuticals AstraZeneca ( AZN )  and Alexion Pharmaceuticals ( ALXN ) entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares ( ADSs )...

Read More

December 14, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 15
  • 16
  • 17
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy